HSBC downgraded Hutchmed (HCM) to Hold from Buy with a $14.70 price target
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCM:
- Hutchmed says NDA for Tazverik granted conditional approval in China
- HUTCHMED’s Strong Financial Performance and Strategic Growth Drive Buy Rating
- Hutchmed Reports Strong 2024 Growth and Profitability
- Hutchmed sees FY25 Oncology/Immunology revenue $350M-$450M
- Hutchmed reports FY24 EPS 22c vs. 59c last year